selected publications
-
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
British journal of haematology.
2018
Academic Article
GET IT
Times cited: 53 -
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Blood cancer journal.
2018
Academic Article
GET IT
Times cited: 28 -
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 313 -
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood.
2016
Academic Article
GET IT
Times cited: 59 -
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2016
Information Resource
GET IT
Times cited: 39 -
Central nervous system involvement in T-cell lymphoma: A single center experience.
Acta oncologica (Stockholm, Sweden).
2016
Academic Article
GET IT
Times cited: 40 -
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2015
Academic Article
GET IT
Times cited: 38 -
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.
Current oncology reports.
2015
Information Resource
GET IT
Times cited: 15 -
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Leukemia & lymphoma.
2015
Academic Article
GET IT
Times cited: 25 -
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
The Lancet. Oncology.
2015
Academic Article
GET IT
Times cited: 152 -
Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
The oncologist.
2014
Academic Article
GET IT
Times cited: 54 -
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
British journal of haematology.
2014
Academic Article
GET IT
Times cited: 26 -
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2014
Academic Article
GET IT
Times cited: 51 -
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Investigational new drugs.
2014
Academic Article
GET IT
Times cited: 64 -
Evolving treatment paradigms for primary mediastinal diffuse large B-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014
Editorial Article
GET IT
Times cited: 5 -
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.
Blood.
2014
Article
GET IT
Times cited: 53 -
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.
Clinical lymphoma, myeloma & leukemia.
2013
Academic Article
GET IT
Times cited: 32 -
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2012
Academic Article
GET IT
Times cited: 173 -
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
Blood.
2011
Academic Article
GET IT
Times cited: 251 -
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 26 -
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010
Academic Article
GET IT
Times cited: 287 -
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
British journal of haematology.
2010
Academic Article
GET IT
Times cited: 86 -
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010
Academic Article
GET IT
Times cited: 41 - Meta-analysis: making sense of maintenance rituximab?. Current oncology reports. 2009 Article GET IT
-
Distress in older patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 106 -
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 170 -
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
British journal of haematology.
2009
Academic Article
GET IT
Times cited: 50 -
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
Clinical pharmacology and therapeutics.
2009
Academic Article
GET IT
Times cited: 35 -
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 126 -
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
British journal of haematology.
2009
Academic Article
GET IT
Times cited: 62 -
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).
Annals of oncology : official journal of the European Society for Medical Oncology.
2009
Academic Article
GET IT
Times cited: 139 - Do six or eight cycles work better with CHOP-14 and rituximab?. Current oncology reports. 2008 Academic Article GET IT
-
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
British journal of haematology.
2008
Academic Article
GET IT
Times cited: 18 -
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
British journal of haematology.
2007
Academic Article
GET IT
Times cited: 73 -
Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.
Annals of oncology : official journal of the European Society for Medical Oncology.
2007
Academic Article
GET IT
Times cited: 4 -
Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice.
Journal of the American Geriatrics Society.
2007
Academic Article
GET IT
Times cited: 119 -
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
British journal of haematology.
2005
Academic Article
GET IT
Times cited: 102 -
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.
Blood.
2005
Academic Article
GET IT
Times cited: 67 -
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2004
Academic Article
GET IT
Times cited: 538 - Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Academic Article GET IT
-
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Blood.
2003
Academic Article
GET IT
Times cited: 191